Golocdacimab (MEDI6570) is a fully human monoclonal antibody that specifically targets the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), with research indicating potential therapeutic applications for mitigating complications associated with type 2 diabetes mellitus and for the prophylaxis of hereditary angioedema (HAE) attacks.